Sexually transmitted diseases and infections

Juntendo University research: Potential immunotherapy approach to cervical cancer

Retrieved on: 
Tuesday, October 27, 2020
Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Gynaecological cancer, Papillomavirus, Carcinogenesis, Sexually transmitted diseases and infections, Human papillomavirus infection, Immunotherapy, Cervical cancer, Papillomaviridae

TOKYO, Oct. 27, 2020 /PRNewswire/ --Researchers at Juntendo University report in the journal Molecular Therapy that specially prepared 'T cells' can be used to suppress cervical cancer.

Key Points: 
  • TOKYO, Oct. 27, 2020 /PRNewswire/ --Researchers at Juntendo University report in the journal Molecular Therapy that specially prepared 'T cells' can be used to suppress cervical cancer.
  • Human papilloma virus (HPV) is known to cause different kinds of cancer, including cervical cancer.
  • For cervical cancer, the scientists identified two proteins, known as E6 and E7, as targets for adoptive T cell therapy these oncoproteins are only expressed by cervical cancer cells, and not found in healthy tissue.
  • Ando and colleagues have now explored a possible immunotherapy for cervical cancer, by developing specially prepared cells, toxic to cancer cells, derived from iPSCs.

Juntendo University research: Potential immunotherapy approach to cervical cancer

Retrieved on: 
Tuesday, October 27, 2020
Cancer, Clinical medicine, Infectious causes of cancer, Medicine, Gynaecological cancer, Papillomavirus, Carcinogenesis, Sexually transmitted diseases and infections, Human papillomavirus infection, Immunotherapy, Cervical cancer, Papillomaviridae

TOKYO, Oct. 27, 2020 /PRNewswire/ --Researchers at Juntendo University report in the journal Molecular Therapy that specially prepared 'T cells' can be used to suppress cervical cancer.

Key Points: 
  • TOKYO, Oct. 27, 2020 /PRNewswire/ --Researchers at Juntendo University report in the journal Molecular Therapy that specially prepared 'T cells' can be used to suppress cervical cancer.
  • Human papilloma virus (HPV) is known to cause different kinds of cancer, including cervical cancer.
  • For cervical cancer, the scientists identified two proteins, known as E6 and E7, as targets for adoptive T cell therapy these oncoproteins are only expressed by cervical cancer cells, and not found in healthy tissue.
  • Ando and colleagues have now explored a possible immunotherapy for cervical cancer, by developing specially prepared cells, toxic to cancer cells, derived from iPSCs.

Orion Biotechnology Successfully Completes Phase 1 Clinical Trial of a First-in-Class Precision Engineered Ligand Analog for HIV Prevention

Retrieved on: 
Thursday, October 15, 2020
Microbicides, Clinical research, Design of experiments, Prevention of HIV/AIDS, Sexually transmitted diseases and infections

The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel.

Key Points: 
  • The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H gel.
  • During the multi-dose phase of the study, participants received study product once daily for five days.
  • The study enrolled a total of 30 healthy volunteers in Warsaw, Poland at the BioVirtus Phase 1 Research Site.
  • Dr. Ian McGowan, Chief Medical Officer at Orion Biotechnology added, Orion would like to thank the study participants, investigators, and researchers for their participation in this study.

Times Square Campaign by 31,000 FT Ad Agency Challenges Herpes Stigma

Retrieved on: 
Tuesday, October 13, 2020
Medical specialties, Sexually transmitted diseases and infections, RTT, Viral diseases, Biology of bipolar disorder, Herpes simplex, Organ systems, Ro, Infectious diseases

Through 10 bold, joyful displays unveiled just before National Herpes Awareness Day, October 13th, 31,000 FT helped FemiClear encourage women to "Open Up" about their experience with herpes and improve their vaginal health.

Key Points: 
  • Through 10 bold, joyful displays unveiled just before National Herpes Awareness Day, October 13th, 31,000 FT helped FemiClear encourage women to "Open Up" about their experience with herpes and improve their vaginal health.
  • The new "Let's Open Up About Herpes" campaign builds on FemiClear's overarching brand purpose of "Joie de hooha" through fearlessly bright video, statistics and features of FemiClear's new genital herpes symptom relief product.
  • In previous years, 31,000 FT brought this core benefit to life for FemiClear through award-winning broadcast and digital advertising.
  • 31,000 FT is a full-service creative advertising agency, partnering with national, regional and local clients, based in Addison, Texas.

Condom Market | Increasing Prevalence of STDs to Boost the Market Growth | Technavio

Retrieved on: 
Friday, October 9, 2020
Retail, Other Retail, RTT, Medical specialties, Sexually transmitted diseases and infections, Clinical medicine, Health, Prevention of HIV/AIDS, Infectious causes of cancer, Sexual health, Sexually transmitted infection, Condom, Female condom, Gonorrhea

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20201009005272/en/
    Technavio has announced its latest market research report titled Global Condom Market 2020-2024 (Graphic: Buiness Wire)
    The prevalence of sexually transmitted diseases such as syphilis, gonorrhea, chlamydia, hepatitis B, genital herpes, and HIV/AIDS is increasing.
  • To help clients improve their market position, this condom market forecast report provides a detailed analysis of the market leaders.
  • As the business impact of COVID-19 spreads, the global condom market 2020-2024 is expected to have Positive and Superior growth.

Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Retrieved on: 
Friday, October 2, 2020
Sexually transmitted diseases and infections, Medical specialties, Infectious diseases, Clinical medicine, Syphilis, Sexually transmitted infection, HIV

HAUPPAUGE, N.Y., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Premarket Approval (PMA) application for the DPP HIV-Syphilis System.

Key Points: 
  • HAUPPAUGE, N.Y., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq:CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the Premarket Approval (PMA) application for the DPP HIV-Syphilis System.
  • The system includes the DPP HIV-Syphilis assay, a multiplex single-use test, and the DPP Micro Reader optical analyzer, and is being offered in the United States immediately.
  • The multiplex DPP HIV-Syphilis System represents a significant step forward in rapid testing for sexually transmitted diseases.
  • Chembios DPP HIV-Syphilis System assists clinicians in diagnosing HIV or syphilis while patients are still at a POC setting.

Genital Herpes Pipeline Review 2020: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Friday, October 2, 2020
Health, Pharmaceutical, Sexually transmitted diseases and infections, Medical specialties, RTT, Infectious diseases, Virology, Herpes, Viral diseases, Biology of bipolar disorder, Herpes simplex, Genital herpes, Herpes simplex research

Genital Herpes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Genital Herpes - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Genital Herpes (Infectious Disease) pipeline guide also reviews the key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects.
  • The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Global Mycoplasma Testing Market (2020 to 2024) - Featuring Agilent Technologies, ATCC & Becton Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 28, 2020
Health, General Health, Sexually transmitted diseases and infections, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Medical specialties, Health, Clinical medicine

The "Global Mycoplasma Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Mycoplasma Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering.
  • The mycoplasma testing market is poised to grow by $ 445.57 million during 2020-2024 progressing at a CAGR of 11% during the forecast period.
  • The reports on mycoplasma testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The market is driven by the increasing focus on R&D of biopharmaceuticals, increasing initiatives and funding for mycoplasma testing and rise in adoption of real-time mycoplasma testing.

AHF Rings Alarm Over Nationwide Shortage of STD Test Kits

Retrieved on: 
Friday, September 25, 2020
AIDS, Health, Medical devices, Consumer, Infectious diseases, Hospitals, Gay & Lesbian, RTT, Sexually transmitted diseases and infections, Infectious causes of cancer, Chlamydiae, Mycoplasma, Sexually transmitted infection, Chlamydia, AIDS Healthcare Foundation, Clinical medicine, Gonorrhea, Health, Medical specialties

AIDS Healthcare Foundation ( AHF ) is raising alarm bells over an extreme nationwide shortage of test kits and laboratory supplies for sexually transmitted infections (STIs, often also referred to as sexually transmitted diseases or STDs), most notably, for chlamydia and gonorrhea nucleic amplification tests (CT/GC NAAT).

Key Points: 
  • AIDS Healthcare Foundation ( AHF ) is raising alarm bells over an extreme nationwide shortage of test kits and laboratory supplies for sexually transmitted infections (STIs, often also referred to as sexually transmitted diseases or STDs), most notably, for chlamydia and gonorrhea nucleic amplification tests (CT/GC NAAT).
  • The CDCs letter also offers Considerations for prioritizing STI testing if test kits are in short supply.
  • AHF, which operates 24 free STD testing and treatment centers, also known as AHF Wellness Centers , in nine states and Washington, D.C., has experienced the test kit shortages firsthand over the past two weeks.
  • The test kit shortage, due in part to supply chain interruptions caused by the pandemic, comes at a crucial and inopportune time.

Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women

Retrieved on: 
Monday, September 14, 2020
Sexually transmitted diseases and infections, RTT, Chlamydiae, Infectious causes of cancer, Medical specialties, Health, Clinical medicine, Gonorrhea, Chlamydia, Preventive healthcare, Chlamydia research

AMPREVENCE evaluated the safety and efficacy of the Company's investigational product candidate EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.

Key Points: 
  • AMPREVENCE evaluated the safety and efficacy of the Company's investigational product candidate EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.
  • The Phase 2b study met its primary and secondary endpoints, with women receiving EVO100 experiencing a relative risk reduction for chlamydia and gonorrhea infection of 50% and 78%, respectively, compared to women receiving placebo.
  • Positive, statistically significant data from the AMPREVENCE study along with a recent data review from the FDA has positioned Evofem to begin a Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women in the fourth quarter of 2020.
  • "EVO100 has the potential to impact the health of millions of women by reducing infection rates of chlamydia and gonorrhea," said Kelly Culwell, M.D., Evofem Biosciences' Chief Medical Officer.